Tocqueville Asset Management L.P. Sells 1,123 Shares of Agilent Technologies Inc (A)

Share on StockTwits

Tocqueville Asset Management L.P. reduced its holdings in shares of Agilent Technologies Inc (NYSE:A) by 0.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 213,237 shares of the medical research company’s stock after selling 1,123 shares during the period. Tocqueville Asset Management L.P. owned 0.07% of Agilent Technologies worth $15,042,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of A. Advisors Capital Management LLC increased its stake in Agilent Technologies by 1.5% during the 2nd quarter. Advisors Capital Management LLC now owns 51,891 shares of the medical research company’s stock valued at $3,209,000 after purchasing an additional 759 shares in the last quarter. SRS Capital Advisors Inc. increased its stake in Agilent Technologies by 75.9% during the 2nd quarter. SRS Capital Advisors Inc. now owns 1,791 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 773 shares in the last quarter. Sterling Capital Management LLC increased its stake in Agilent Technologies by 0.8% during the 3rd quarter. Sterling Capital Management LLC now owns 104,765 shares of the medical research company’s stock valued at $7,390,000 after purchasing an additional 850 shares in the last quarter. State of Alaska Department of Revenue increased its stake in Agilent Technologies by 1.5% during the 3rd quarter. State of Alaska Department of Revenue now owns 61,196 shares of the medical research company’s stock valued at $4,315,000 after purchasing an additional 887 shares in the last quarter. Finally, First Republic Investment Management Inc. increased its stake in Agilent Technologies by 5.9% during the 2nd quarter. First Republic Investment Management Inc. now owns 17,255 shares of the medical research company’s stock valued at $1,067,000 after purchasing an additional 969 shares in the last quarter.

Shares of A stock opened at $71.42 on Thursday. Agilent Technologies Inc has a 52 week low of $60.42 and a 52 week high of $75.11. The company has a market capitalization of $23.24 billion, a PE ratio of 25.54, a P/E/G ratio of 2.04 and a beta of 1.36. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.29 and a quick ratio of 2.74.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 19th. The medical research company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. Agilent Technologies had a net margin of 6.43% and a return on equity of 19.84%. The firm had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the business posted $0.67 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities research analysts anticipate that Agilent Technologies Inc will post 3.04 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 23rd. Stockholders of record on Monday, December 31st will be paid a $0.164 dividend. The ex-dividend date of this dividend is Friday, December 28th. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.15. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.92%. Agilent Technologies’s payout ratio is currently 21.51%.

Agilent Technologies announced that its Board of Directors has initiated a stock repurchase plan on Monday, November 19th that allows the company to buyback $1.75 billion in shares. This buyback authorization allows the medical research company to purchase up to 8.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its stock is undervalued.

A number of research firms have weighed in on A. Zacks Investment Research lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. ValuEngine upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, November 2nd. Morgan Stanley raised their price objective on shares of Agilent Technologies from $83.00 to $84.00 and gave the company an “overweight” rating in a research note on Wednesday, August 15th. Deutsche Bank raised their price objective on shares of Agilent Technologies from $77.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, August 15th. Finally, Cleveland Research lowered shares of Agilent Technologies from a “buy” rating to a “neutral” rating in a research note on Monday, November 12th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $78.75.

In related news, CEO Michael R. Mcmullen sold 15,923 shares of the business’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $73.20, for a total transaction of $1,165,563.60. Following the completion of the sale, the chief executive officer now directly owns 492,546 shares in the company, valued at $36,054,367.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dominique Grau sold 8,902 shares of the business’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $74.00, for a total transaction of $658,748.00. Following the sale, the insider now owns 103,387 shares of the company’s stock, valued at $7,650,638. The disclosure for this sale can be found here. Insiders sold 34,683 shares of company stock valued at $2,499,491 over the last quarter.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.fairfieldcurrent.com/news/2018/12/06/tocqueville-asset-management-l-p-sells-1123-shares-of-agilent-technologies-inc-a.html.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

Read More: Is a Roth IRA right for you?

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply